Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous

Chen Chu1, Lan He1, Yi-Xiang Lin1

  • 1Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, 399 Wan Yuan Road, Shanghai, 201102, China.

Insights

Kawasaki disease can cause rare peripheral artery aneurysms alongside coronary artery aneurysms. Prompt antithrombotic therapy is crucial for managing these systemic artery aneurysms and preventing complications.

Area of Science:

  • Cardiovascular Medicine
  • Pediatric Rheumatology
  • Vascular Surgery

Background:

  • Kawasaki disease (KD) is a vasculitis affecting medium-sized arteries, primarily causing coronary artery aneurysms (CAAs).
  • Peripheral systemic artery aneurysms (SAAs) are rare complications of KD, often associated with severe or refractory cases.
  • Thrombotic events in SAAs are infrequently reported in the literature.

Purpose of the Study:

  • To report a case of giant bilateral axillary artery aneurysms (AAAs) in a pediatric patient with a history of Kawasaki disease.
  • To emphasize the importance of evaluating for peripheral SAAs in KD patients, even those with seemingly uncomplicated coronary artery aneurysms.
  • To highlight the critical role of antithrombotic therapy in managing both CAAs and SAAs in KD.

Main Methods:

  • A 10-month-old boy with KD and bilateral CAAs presented with suspected axillary artery pseudoaneurysms.
  • Diagnostic imaging included echocardiogram, ultrasound, and angiography to assess the extent of aneurysms and thrombus formation.
  • Treatment involved prostaglandin, aspirin, low molecular weight heparin/warfarin, and metoprolol to promote collateral circulation and prevent thrombosis.

Main Results:

  • The patient was diagnosed with giant bilateral AAAs, with the left AAA showing complete occlusion and significant thrombus.
  • Medical management led to significant improvement in the left upper limb's temperature and movement.
  • Follow-up at 7 months showed continued improvement and no cardiovascular events, with stable aneurysm imaging.

Conclusions:

  • Peripheral SAAs should be evaluated in all Kawasaki disease patients with CAAs, irrespective of treatment course.
  • Antithrombotic therapy is essential for managing both large non-aortic SAAs and CAAs in KD.
  • Early detection and management of SAAs can prevent severe complications and improve patient outcomes.
Abstract